Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury.
The purpose of this study was to investigate hemoglobin and iron handling after subarachnoid hemorrhage (SAH), examine the relationship between iron and neuroglial cell changes, and determine whether deferoxamine (DFX) can reduce SAH-induced injury. The SAH was induced in Sprague-Dawley rats (n=110) using an endovascular perforation technique. Animals were treated with DFX (100 mg/kg) or vehicle 2 and 6 hours after SAH induction followed by every 12 hours for 3 days. Rats were killed at 6 hours, Days 1 and 3 to determine nonheme iron and examine iron-handling proteins using Western blot and immunohistochemistry. 8-Hydroxyl-2'-deoxyguanosine and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining were performed to assess oxidative DNA damage and neuronal cell death. After SAH, marked heme-oxygenase-1 (HO-1) upregulation at Day 3 (P<0.01) was accompanied by elevated nonheme iron (P<0.01), transferrin (Tf) (P<0.01), Tf receptor (P<0.05), and ferritin levels (P<0.01). Deferoxamine treatment reduced SAH-induced mortality (12% versus 29%, P<0.05), brain nonheme iron concentration, iron-handling protein expression, oxidative stress, and neuronal cell death at Day 3 (P<0.01) after SAH. These results suggest that iron overload in the acute phase of SAH causes oxidative injury leading to neuronal cell death. Deferoxamine effectively reduced oxidative stress and neuronal cell death, and may be a potential therapeutic agent for SAH.
Lee
Jin-Yul
JY
Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan 48109-2200, USA. jinannarbor@gmail.com
Keep
Richard F
RF
He
Yangdong
Y
Sagher
Oren
O
Hua
Ya
Y
Xi
Guohua
G
D000818:Animals; D015153:Blotting, Western; D001921:Brain / Q000378:metabolism*; D016923:Cell Death / Q000187:drug effects; D004249:DNA Damage; D003676:Deferoxamine / Q000627:therapeutic use*; D051547:Heme Oxygenase-1 / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism*; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008297:Male; D009474:Neurons / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D011990:Receptors, Transferrin / Q000378:metabolism; D013345:Subarachnoid Hemorrhage / Q000378:metabolism* / Q000401:mortality; D013997:Time Factors; D014168:Transferrin / Q000378:metabolism
D006454:Hemoglobins; D007502:Iron Chelating Agents; D011990:Receptors, Transferrin; D014168:Transferrin; D007501:Iron; D051547:Heme Oxygenase-1; D003676:Deferoxamine